Our current understanding of the complex relationship between menopausal hormone therapy (MHT) and cardiovascular disease (CVD) risk has been largely informed by detailed analyses in the WHI, the largest-ever randomised, placebo‐controlled trial evaluating MHT in postmenopausal women.

The WHI studies caused drastic changes in the medical approach to postmenopausal women, although subsequent studies have tended to confirm the validity of clinical approaches predating WHI.

Please sign in to read more